Return to Trial Database

HCRN-LUN17-126

Randomized phase II study of durvalumab or durvalumab plus chemotherapy in Kras mutation positive and PD-L1 high (>/= 50%) NSCLC patients

Status

Study Completed

Cancer Type(s)

Study Contact

Trial Locations

All sites in which the trial HCRN-LUN17-126 being conducted in.

No data was found